A recent profile by The New York Times celebrated Medvi, a burgeoning telehealth enterprise, as a testament to the transformative…
Read More
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The recent trajectory of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, casts a…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The recent profile of Medvi by The New York Times earlier this month highlighted the company as a prime example…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
The narrative of MEDVi, an AI-powered telehealth startup, recently unfolded with a stark duality: hailed by The New York Times…
Read More
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception
A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…
Read More
MEDVi Under Scrutiny Following FDA Warning, Deceptive AI Advertising, and Multiple Lawsuits
In 2024, OpenAI CEO Sam Altman famously predicted that a single entrepreneur, leveraging the transformative power of artificial intelligence, could…
Read More
Medvi’s QUAD Erectile Dysfunction Cocktail Raises Significant Safety Concerns Amidst Regulatory Scrutiny and Questionable Marketing Practices
The burgeoning telehealth industry, lauded for its potential to democratize healthcare access, is facing intensified scrutiny as companies push the…
Read More
How Medvi Built a $1.8 Billion Telehealth Empire in Regulatory Blind Spots: A Deep Dive into AI, Compounding, and Fragmented Oversight
The rapid ascent of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, has thrust…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
A burgeoning telehealth startup, MEDVi, heralded by The New York Times as a prime example of an AI-powered venture reaching…
Read More
